Drug Eruptions (eBook, PDF)
Statt 235,39 €**
160,49 €
**Preis der gedruckten Ausgabe (Gebundenes Buch)
inkl. MwSt. und vom Verlag festgesetzt.
0 °P sammeln
Drug Eruptions (eBook, PDF)
- Format: PDF
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei
bücher.de, um das eBook-Abo tolino select nutzen zu können.
Hier können Sie sich einloggen
Hier können Sie sich einloggen
Sie sind bereits eingeloggt. Klicken Sie auf 2. tolino select Abo, um fortzufahren.
Bitte loggen Sie sich zunächst in Ihr Kundenkonto ein oder registrieren Sie sich bei bücher.de, um das eBook-Abo tolino select nutzen zu können.
Cutaneous adverse drug reactions are common and range from the benign to those which are life-threatening. The clinical presentation of these dermatoses is varied and many may mimic common skin conditions. Consequently, diagnosis in drug-induced skin disease is challenging and the treatment considerations are complex. This book aims to bridge the divide between dermatology and allergy by providing a comprehensive review on the pathomechanisms and clinical features of cutaneous adverse drug reactions. Broken up into three distinct sections: General Considerations, Reaction Patterns, and Special…mehr
- Geräte: PC
- ohne Kopierschutz
- eBook Hilfe
- Größe: 23.45MB
- Upload möglich
Andere Kunden interessierten sich auch für
- Urticaria and Angioedema (eBook, PDF)96,29 €
- Gerald W. VolcheckClinical Allergy (eBook, PDF)106,99 €
- Anaphylaxis and Hypersensitivity Reactions (eBook, PDF)106,99 €
- Urticaria and Angioedema (eBook, PDF)79,95 €
- Challenging Cases in Allergy and Immunology (eBook, PDF)128,39 €
- Challenging Cases in Allergic and Immunologic Diseases of the Skin (eBook, PDF)106,99 €
- Brian A. BaldoDrug Allergy (eBook, PDF)171,19 €
-
-
-
Cutaneous adverse drug reactions are common and range from the benign to those which are life-threatening. The clinical presentation of these dermatoses is varied and many may mimic common skin conditions. Consequently, diagnosis in drug-induced skin disease is challenging and the treatment considerations are complex. This book aims to bridge the divide between dermatology and allergy by providing a comprehensive review on the pathomechanisms and clinical features of cutaneous adverse drug reactions. Broken up into three distinct sections: General Considerations, Reaction Patterns, and Special Drug Categories, these chapters cover the common and rare adverse skin reactions and provide information on recent advances - particularly immunopathology and pharmacogenetics - as well as highlighting new adverse drug signals and novel therapies. Drug Eruptions is a must-have resource for dermatologists, allergists, internal physicians and general practitioners.
Produktdetails
- Produktdetails
- Verlag: Springer International Publishing
- Erscheinungstermin: 27. Oktober 2022
- Englisch
- ISBN-13: 9783031093883
- Artikelnr.: 66264616
- Verlag: Springer International Publishing
- Erscheinungstermin: 27. Oktober 2022
- Englisch
- ISBN-13: 9783031093883
- Artikelnr.: 66264616
Haur Yueh Lee, MBBS, MRCP (UK), FAMS(Dermatology) Singapore General Hospital Department of Dermatology Singapore, 169856, Singapore
Daniel Creamer, MD FRCP King’s College Hospital Department of Dermatology Denmark Hill London SE5 9RS, UK
Daniel Creamer, MD FRCP King’s College Hospital Department of Dermatology Denmark Hill London SE5 9RS, UK
Section I: General Considerations.- Chapter 1: Pharmacogenetics of Cutaneous Adverse Drug Reactions.- Chapter 2: Mechanisms of Drug Hypersensitivity.- Chapter 3: Histopathology of Cutaneous Adverse Drug Reactions.- Chapter 4: Skin Tests in Evaluating Drug Eruptions.- Chapter 5: In vitro Drug Allergy Testing.- Section II: Reaction Patterns.- Chapter 6: Drug-induced urticaria.- Chapter 7: Exanthematous Drug Eruptions.- Chapter 8: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.- Chapter 9: Acute Generalized Exanthematous Pustulosis.- Chapter 10: Drug Reaction Eosinophilia and Systemic Symptoms (DRESS).- Chapter 11: Fixed Drug Eruptions and Generalized Bullous Fixed Drug Eruptions.- Chapter 12: Lichenoid Drug Eruptions.- Chapter 13: Drug-induced Connective Tissue Disorders.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 17: Drug-induced Photosensitivity.- Chapter 18: Drug-induced Pruritus Without Primary Rash.- Chapter 19: Drug-induced Nail Changes.- Chapter 20: Drug-induced Hair Changes.- Chapter 21: Drug-induced Pigmentary Disorders.- Section III: Special Drug Categories.- Chapter 22: Immediate and Delayed Reactions to Beta-lactams.- Chapter 23: Hypersensitivity Reactions to Iodinated Radiocontrast Media.- Chapter 24: Cutaneous Adverse Reactions to Biologic Agents.- Chapter 25: Cutaneous Reactions to Oncologic Targeted Therapy.- Chapter 26 :Cutaneous Reactions to Oncologic Immunotherapy.
Section I: General Considerations.- Chapter 1: Pharmacogenetics of Cutaneous Adverse Drug Reactions.- Chapter 2: Mechanisms of Drug Hypersensitivity.- Chapter 3: Histopathology of Cutaneous Adverse Drug Reactions.- Chapter 4: Skin Tests in Evaluating Drug Eruptions.- Chapter 5: In vitro Drug Allergy Testing.- Section II: Reaction Patterns.- Chapter 6: Drug-induced urticaria.- Chapter 7: Exanthematous Drug Eruptions.- Chapter 8: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.- Chapter 9: Acute Generalized Exanthematous Pustulosis.- Chapter 10: Drug Reaction Eosinophilia and Systemic Symptoms (DRESS).- Chapter 11: Fixed Drug Eruptions and Generalized Bullous Fixed Drug Eruptions.- Chapter 12: Lichenoid Drug Eruptions.- Chapter 13: Drug-induced Connective Tissue Disorders.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 17: Drug-induced Photosensitivity.- Chapter 18: Drug-induced Pruritus Without Primary Rash.- Chapter 19: Drug-induced Nail Changes.- Chapter 20: Drug-induced Hair Changes.- Chapter 21: Drug-induced Pigmentary Disorders.- Section III: Special Drug Categories.- Chapter 22: Immediate and Delayed Reactions to Beta-lactams.- Chapter 23: Hypersensitivity Reactions to Iodinated Radiocontrast Media.- Chapter 24: Cutaneous Adverse Reactions to Biologic Agents.- Chapter 25: Cutaneous Reactions to Oncologic Targeted Therapy.- Chapter 26 :Cutaneous Reactions to Oncologic Immunotherapy.
Section I: General Considerations.- Chapter 1: Pharmacogenetics of Cutaneous Adverse Drug Reactions.- Chapter 2: Mechanisms of Drug Hypersensitivity.- Chapter 3: Histopathology of Cutaneous Adverse Drug Reactions.- Chapter 4: Skin Tests in Evaluating Drug Eruptions.- Chapter 5: In vitro Drug Allergy Testing.- Section II: Reaction Patterns.- Chapter 6: Drug-induced urticaria.- Chapter 7: Exanthematous Drug Eruptions.- Chapter 8: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.- Chapter 9: Acute Generalized Exanthematous Pustulosis.- Chapter 10: Drug Reaction Eosinophilia and Systemic Symptoms (DRESS).- Chapter 11: Fixed Drug Eruptions and Generalized Bullous Fixed Drug Eruptions.- Chapter 12: Lichenoid Drug Eruptions.- Chapter 13: Drug-induced Connective Tissue Disorders.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 17: Drug-induced Photosensitivity.- Chapter 18: Drug-induced Pruritus Without Primary Rash.- Chapter 19: Drug-induced Nail Changes.- Chapter 20: Drug-induced Hair Changes.- Chapter 21: Drug-induced Pigmentary Disorders.- Section III: Special Drug Categories.- Chapter 22: Immediate and Delayed Reactions to Beta-lactams.- Chapter 23: Hypersensitivity Reactions to Iodinated Radiocontrast Media.- Chapter 24: Cutaneous Adverse Reactions to Biologic Agents.- Chapter 25: Cutaneous Reactions to Oncologic Targeted Therapy.- Chapter 26 :Cutaneous Reactions to Oncologic Immunotherapy.
Section I: General Considerations.- Chapter 1: Pharmacogenetics of Cutaneous Adverse Drug Reactions.- Chapter 2: Mechanisms of Drug Hypersensitivity.- Chapter 3: Histopathology of Cutaneous Adverse Drug Reactions.- Chapter 4: Skin Tests in Evaluating Drug Eruptions.- Chapter 5: In vitro Drug Allergy Testing.- Section II: Reaction Patterns.- Chapter 6: Drug-induced urticaria.- Chapter 7: Exanthematous Drug Eruptions.- Chapter 8: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.- Chapter 9: Acute Generalized Exanthematous Pustulosis.- Chapter 10: Drug Reaction Eosinophilia and Systemic Symptoms (DRESS).- Chapter 11: Fixed Drug Eruptions and Generalized Bullous Fixed Drug Eruptions.- Chapter 12: Lichenoid Drug Eruptions.- Chapter 13: Drug-induced Connective Tissue Disorders.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 14: Drug-induced Vasculitis.- Chapter 15: Drug-induced Autoimmune Bullous Diseases.- Chapter 16: Other Drug-induced Inflammatory Skin Reactions.- Chapter 17: Drug-induced Photosensitivity.- Chapter 18: Drug-induced Pruritus Without Primary Rash.- Chapter 19: Drug-induced Nail Changes.- Chapter 20: Drug-induced Hair Changes.- Chapter 21: Drug-induced Pigmentary Disorders.- Section III: Special Drug Categories.- Chapter 22: Immediate and Delayed Reactions to Beta-lactams.- Chapter 23: Hypersensitivity Reactions to Iodinated Radiocontrast Media.- Chapter 24: Cutaneous Adverse Reactions to Biologic Agents.- Chapter 25: Cutaneous Reactions to Oncologic Targeted Therapy.- Chapter 26 :Cutaneous Reactions to Oncologic Immunotherapy.